This study compared public procurement and ex-factory prices for 19 cancer medicines in five Latin American countries (Brazil, Chile, Colombia, Mexico, and Peru) and 11 European countries (Austria, France, Germany, Greece, Hungary, the Netherlands, Poland, Romania, Spain, Sweden, and the UK) and affordability. The prices of cancer medicines varied considerably between countries. In European countries with higher levels of income, PPP-adjusted prices tended to be lower than in European countries of lower income and LATAM countries. Nearly all surveyed medicines were considered unaffordable in most countries.
See the article:
Moye-Holz D, Vogler S.: Comparison of Prices and Affordability of Cancer Medicines in 16 Countries in Europe and Latin America. Applied Health Economics and Health Policy 2021